相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Projecting future drug expenditures-2011
Fred Doloresco et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2011)
Genetic determinants of anticancer drug activity: towards a global approach to personalized cancer medicine
Alexander Picker et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2011)
Bevacizumab Treatment for Solid Tumors Boon or Bust?
Daniel F. Hayes
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Treatment-Related Mortality With Bevacizumab in Cancer Patients A Meta-analysis
Vishal Ranpura et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Big Costs for Little Gain in Ovarian Cancer
Martee L. Hensley
JOURNAL OF CLINICAL ONCOLOGY (2011)
At What Cost Does a Potential Survival Advantage of Bevacizumab Make Sense for the Primary Treatment of Ovarian Cancer? A Cost-Effectiveness Analysis
David E. Cohn et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
BRAF targeted therapy changes the treatment paradigm in melanoma
Antoni Ribas et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Genome-wide genetic marker discovery and genotyping using next-generation sequencing
John W. Davey et al.
NATURE REVIEWS GENETICS (2011)
Once on 'Fast Track,' Avastin Now Derailed
Jennifer Couzin-Frankel et al.
SCIENCE (2011)
The BATTLE Trial: Personalizing Therapy for Lung Cancer
Edward S. Kim et al.
CANCER DISCOVERY (2011)
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
M. Reck et al.
ANNALS OF ONCOLOGY (2010)
Biomarkers of angiogenesis and their role in the development of VEGF inhibitors
N. Murukesh et al.
BRITISH JOURNAL OF CANCER (2010)
ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time
David E. Gerber et al.
CANCER CELL (2010)
Biologically Targeted Cancer Therapy and Marginal Benefits: Are We Making Too Much of Too Little or Are We Achieving Too Little by Giving Too Much?
Tito Fojo et al.
CLINICAL CANCER RESEARCH (2010)
Pyridoxine Is Not Effective to Prevent Hand-Foot Syndrome Associated With Capecitabine Therapy: Results of a Randomized, Double-Blind, Placebo-Controlled Study
Yoon-Koo Kang et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
Hedy Lee Kindler et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
David W. Miles et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
Scott Kopetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Resistance to Imatinib: Mutations and Beyond
Paul La Rosee et al.
SEMINARS IN HEMATOLOGY (2010)
THE POTENTIAL IMPACT OF COMPARATIVE EFFECTIVENESS RESEARCH ON US HEALTH CARE EXPENDITURES
Daniella J. Perlroth et al.
DEMOGRAPHY (2010)
Medical Bankruptcy in the United States, 2007: Results of a National Study
David U. Himmelstein et al.
AMERICAN JOURNAL OF MEDICINE (2009)
Clinical and economic impact of the nonresponder phenomenon - implications for systems based discovery
David B. Jackson
DRUG DISCOVERY TODAY (2009)
Molecular perspectives on the non-responder phenomenon
David B. Jackson
DRUG DISCOVERY TODAY (2009)
Effects of Food on Bioavailability of Lapatinib: Useful Data, Wrong Conclusion
Ian F. Tannock
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAiL
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care
Neal J. Meropol et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question
Tito Fojo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs
Peter B. Bach
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Cost of cancer care: The patient perspective
Paula Kim
JOURNAL OF CLINICAL ONCOLOGY (2007)
Cost of cancer care: Issues and implications
Neal J. Meropol et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
EPHB4 and survival of colorectal cancer patients
Veronica Davalos et al.
CANCER RESEARCH (2006)
Opinion - The influence of bio-behavioural factors on tumour biology: pathways and mechanisms
MH Antoni et al.
NATURE REVIEWS CANCER (2006)
EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival
G Xia et al.
ONCOGENE (2006)
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry
KY Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Timeline - Chemotherapy and the war on cancer
BA Chabner et al.
NATURE REVIEWS CANCER (2005)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Maximizing the potential of bevacizumab in cancer treatment
E Bergsland et al.
ONCOLOGIST (2004)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
分享论文
